The noninvasive nature of photodynamic therapy (PDT) enables the preservation of organ function in cancer patients. However, PDT is impeded by hypoxia in the tumor microenvironment (TME) caused by high intracellular oxygen (O-2) consumption and distorted tumor blood vessels. Therefore, increasing oxygen generation in the TME would be a promising methodology for enhancing PDT. Herein, we proposed a concept of ferroptosis-promoted PDT based on the biochemical characteristics of cellular ferroptosis, which improved the PDT efficacy significantly by producing reactive oxygen species (ROS) and supplying O-2 sustainably through the Fenton reaction. In contrast to traditional strategies that increase O(2 )based on decomposition of limited concentration of hydrogen peroxide (H2O2), our methodology could maintain the concentration of H2O2 and O-2 through the Fenton reaction.
Methods: For its association with sensitivity to ferroptosis, solute carrier family 7 member 11 (SLC7A11) expression was characterized by bioinformatics analysis and immunohistochemistry of oral tongue squamous cell carcinoma (OTSCC) specimens. Afterwards, the photosensitizer chlorin e6 (Ce6) and the ferroptosis inducer erastin were self-assembled into a novel supramolecular Ce6-erastin nanodrug through hydrogen bonding and pi-pi stacking. Then, the obtained Ce6-erastin was extensively characterized and its anti-tumor efficacy towards OTSCC was evaluated both in vitro and in vivo.
Results: SLC7A11 expression is found to be upregulated in OTSCC, which is a potential target for ferroptosis-mediated OTSCC treatment. Ce6-erastin nanoparticles exhibited low cytotoxicity to normal tissues. More significantly, The over-accumulated intracellular ROS, increased O-2 concentration and inhibited SLC7A11 expression lead to enhanced toxicity to CAL-27 cells and satisfactory antitumor effects to xenograft tumour mouse model upon irradiation.
Conclusion: Our ferroptosis promoted PDT approach markedly enhances anticancer actions by relieving hypoxia and promoting ROS production, thereby our work provides a new approach for overcoming hypoxia-associated resistance of PDT in cancer treatment.
[1]Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Coll Stomatol,Sch Med, Dept Oral & Maxillofacial Head Neck Oncol,Dept La, Shanghai 200011, Peoples R China;
[2]Natl Clin Res Ctr Oral Dis, Shanghai 200011, Peoples R China;
[3]Shanghai Key Lab Stomatol, Shanghai 200011, Peoples R China;
[4]Shanghai Res Inst Stomatol, Shanghai 200011, Peoples R China;
[5]Shanghai Jiao Tong Univ, Sch Chem & Chem Engn, Shanghai Key Lab Mol Engn Chiral Drugs, Shanghai 200240, Peoples R China;
[6]Fudan Univ, Huashan Hosp, Dept Dermatol, Shanghai 200040, Peoples R China;
[7]Shanghai Inst Technol, Sch Chem & Environm Engn, Shanghai 201418, Peoples R China
(8.0+极速模式)